You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Anti-cardiac Troponin I (phospho) antibody [5E6] (ab8291)

Overview

  • Product nameAnti-cardiac Troponin I (phospho) antibody [5E6]See all Cardiac Troponin I primary antibodies ...
  • Description
    Mouse monoclonal [5E6] to cardiac Troponin I (phospho)
  • SpecificityPhosphorylated form of cardiac troponin I
  • Tested applicationsWB, ELISA more details
  • Species reactivity
    Reacts with: Human, Pig
  • Immunogen

    Phosphorylated form of cardiac troponin I (phosphorylated in the 22nd and 23rd position)

  • General notes


    This antibody detects the phosphorylated form of cardiac troponin

Properties

Applications

Our Abpromise guarantee covers the use of ab8291 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Notes
WB WB: Use at an assay dependent dilution. Predicted molecular weight: 25 kDa.
ELISA ELISA: Use at an assay dependent dilution.

Target

  • FunctionTroponin I is the inhibitory subunit of troponin, the thin filament regulatory complex which confers calcium-sensitivity to striated muscle actomyosin ATPase activity.
  • Involvement in diseaseDefects in TNNI3 are the cause of cardiomyopathy familial hypertrophic type 7 (CMH7) [MIM:613690]. Familial hypertrophic cardiomyopathy is a hereditary heart disorder characterized by ventricular hypertrophy, which is usually asymmetric and often involves the interventricular septum. The symptoms include dyspnea, syncope, collapse, palpitations, and chest pain. They can be readily provoked by exercise. The disorder has inter- and intrafamilial variability ranging from benign to malignant forms with high risk of cardiac failure and sudden cardiac death.
    Defects in TNNI3 are the cause of cardiomyopathy familial restrictive type 1 (RCM1) [MIM:115210]. RCM1 is an heart muscle disorder characterized by impaired filling of the ventricles with reduced diastolic volume, in the presence of normal or near normal wall thickness and systolic function.
    Defects in TNNI3 are the cause of cardiomyopathy dilated type 2A (CMD2A) [MIM:611880]. Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.
    Defects in TNNI3 are the cause of cardiomyopathy dilated type 1FF (CMD1FF) [MIM:613286]. Dilated cardiomyopathy is a disorder characterized by ventricular dilation and impaired systolic function, resulting in congestive heart failure and arrhythmia. Patients are at risk of premature death.
  • Sequence similaritiesBelongs to the troponin I family.
  • Target information above from: UniProt accession P19429 The UniProt Consortium
    The Universal Protein Resource (UniProt) in 2010
    Nucleic Acids Res. 38:D142-D148 (2010) .

    Information by UniProt
  • Database links
  • Alternative names
      cardiac muscle antibodyCardiac troponin I antibodyCardiomyopathy, familial hypertrophic, 7, included antibody
      CMD1FF antibodyCMD2A antibodyCMH7 antibodycTnI antibodyFamilial hypertrophic cardiomyopathy 7 antibodyMGC116817 antibodyRCM1 antibodyTn1 antibodyTni antibodyTNN I3 antibodyTNNC 1 antibodyTNNC1 antibodyTNNI3 antibodyTNNI3 antibodyTNNI3_HUMAN antibodyTroponin I antibodyTroponin I cardiac antibodyTroponin I cardiac muscle antibodyTroponin I cardiac muscle isoform antibodyTroponin I type 3 cardiac antibodytroponin I, cardiac 3 antibodyTroponinI antibodyTtroponin I type 3 (cardiac) antibody
    see all

References for Anti-cardiac Troponin I (phospho) antibody [5E6] (ab8291)

This product has been referenced in:
  • Sarin V  et al. Ca²? sensitization of cardiac myofilament proteins contributes to exercise training-enhanced myocardial function in a porcine model of chronic occlusion. Am J Physiol Heart Circ Physiol 301:H1579-87 (2011). WB ; Pig . Read more (PubMed: 21856915) »
  • Du J  et al. Impaired relaxation is the main manifestation in transgenic mice expressing a restrictive cardiomyopathy mutation, R193H, in cardiac TnI. Am J Physiol Heart Circ Physiol 294:H2604-13 (2008). Read more (PubMed: 18408133) »

See all 2 Publications for this product

Product Wall

Displaying 1 - 4 of 4 results for Abreviews and Q&A

Thank you for your email. The ab9936 product is a peptide which can be used to block antibodies ab7829, ab8290 and ab8291. This peptide can be used to block these antibodies irrespective of applications e.g. It is suitable to use with antibodies in...

Read More

Thank you for your email. Ab8290 does NOT react with rabbit, and ab8291 has only so far been tested for cross-reactivity with human (not yet tested in rabbit). I unfortunately cannot find another cardiac Troponin I antibody in our catalog that is sp...

Read More

The specific epitope has not been mapped but it is situated in the sites of phosphorylation, which are in the 22nd and 23rd position

This antibody is raised against the human protein and species cross-reactivity has not been tested. We recommend 20 ug/ml working concentration for WB.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"